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Printzmetal angina1. Introduction
Myocardial ischaemia results from a direct mismatch between
oxygen supply and demand, commonly arising as a result of coronary
atherosclerosis, microvascular dysfunction or acute thrombosis and lu-
minal obstruction. However, transient ischaemia may also occur due
to coronary spasm leading to acute and unexpected myocardial ischae-
mia without obvious visible coronary pathology. Aside from symptoms
of chest pain, coronary spasm can cause infarction, LV impairment, pro-
mote life threatening arrhythmias and ultimately sudden cardiac death.
While therapeutic options are available, controversies exist around
diagnosis, pathology, management and prognosis. This review summa-
rises some of the common questions in this area. In particular we
explore and discuss the available evidence for the pharmacological
treatment of coronary spasm, and strategies for identiﬁcation and
management of very high risk patients to try and reduce the incidence
of sudden premature death.2. Overview of coronary spasm
Coronary spasm, also known as variant or Printzmetal's angina,
represents a syndrome characterised by sudden chest pain due to
epicardial coronary artery spasm which usually leads to transienthe reliability and freedom from
ion.
oronarica, IRCCS Ospedale San
land Ltd. This is an open access articlmyocardial ischemia, with chest pain and ECG changes. It differs from
traditional stable angina pectoris, symptomatically in that it is not
directly related to effort and pathologically as it is not driven by athero-
sclerosis and lumen encroachment within the coronary vasculature
(Table 1).
The actual prevalence of the condition in the general population re-
mains largely unknown, primarily due to challenges in diagnosis. How-
ever, in contrast to traditional angina pectoris, it appears to be less
frequent, afﬂicts younger patients and females more than males [1–5].
It is alsowidely recognised that individuals from Japan tend to have sig-
niﬁcantly greater coronary reactivity and tendency to spasm than those
from other nations. This is borne out by a greater incidence and preva-
lence of the syndrome in this region, with a concurrently lower rate of
coronary atherosclerotic disease compared with those in Europe
[6–14]. Coronary spasm is also associated with smoking, cocaine, am-
phetamine, marijuana and alcohol consumption, which can often ex-
plain myocardial infarction in young patients with few traditional
cardiovascular risk factors. Notably, chemotherapy and anti-migraine
drugs may also induce coronary spasm and cautions are listed for
these agents (Table 2) [15–21].
A key feature of coronary spasm is its temporally transient nature
which often leads to difﬁculties in diagnosis. Intriguingly, spasm occur-
rences tend to follow a circadian pattern, being most frequent during
the night or early morning [1–5]. This is an important feature of the his-
tory and often used in diagnostic criterion [13].
Anatomically, coronary spasm may be focal or diffuse within a ves-
sel, may affect multiple vessels and may migrate from site to site.
Mixed type spasm is deﬁned as multi-vessel spasm in which at least
one coronary artery has a focal spasm and the other a diffuse spasm.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Common differences between coronary spasm and chronic stable angina.
Coronary spasm Chronic stable angina
Frequency Less More frequent
Age Younger Older
Sex Female Male
Ethnicity Japanese No speciﬁc prevalence
Risk factors Smoking, drug addiction, alcohol,
hyperventilation, beta blockers
Classic cardiovascular risk factor
Circadian
pattern
Night–early morning No
Exertion/rest Exertion/rest Exertion
ECG ST segment elevation ST segment depression
48 M. Slavich, R.S. Patel / IJC Heart & Vasculature 10 (2016) 47–53Takagi et al. reported the presence of multi-vessel spasm in 32% of their
cohort, and of these the ones with mixed type spasm had the highest
risk ofMajor Adverse Cardiovascular Events (MACE), includingmyocar-
dial infarction [14]. Additionally, they reported that right coronary
spasm was signiﬁcantly associated with ventricular arrhythmias com-
pared with other vessels [14]. Patients with diffuse spasm are
generally less likely to respond to therapy and have a worse outcome,
presumably because of advanced and extensive vasomotor dysfunction
of the coronary circulation [14,22–23]. Although infarction sizes in the
context of spasm are usually relatively small, due to early spontaneous
reperfusion once spasm has subsided, the risk of fatal arrhythmias
remains a feared complication.
3. Pathophysiology
The exact underlying pathology predisposing to spasm is not clearly
understood, but a complex interplay of factors is postulated to be
responsible for the highly heterogeneous clinical manifestations, natu-
ral history and response to therapy. Although a constellation of such
precipitating factors have been proposed (genetic background, vagal
and sympathetic activity alteration, magnesium deﬁciency, enhanced
oxidative stress, inﬂammation), the most established and accepted
mechanisms are endothelial dysfunction, nitric oxide (NO) release and
enhanced vascular smoothmuscle cell contractilitywhich all determine
vascular tone [15,22–30].
3.1. Atherosclerosis and spasm — are they mutually exclusive?
Coronary spasm often occurs in angiographically normal arteries but
can also be found in those with mild and more severe atherosclerotic
stenosis. With increasing availability of angiography and more patients
undergoing testing, presence of concurrent atherosclerotic plaque is not
uncommon, raising the question as towhether (1) spasm is the cause of
chest pain, (2) plaque promotes spasmand (3) if patientswith both fare
worse?
Early studies on coronary spasm patients reported that the pres-
ence of co-existent severe coronary disease with coronary spasm
was associated with an adverse prognosis [23,32–39]. However,
long term followup data has also revealed that the presence of
even non-signiﬁcant stenosis impacts unfavourably on patient out-
come [14]. Notably, the presence of subtle atherosclerotic inﬁltrationTable 2
Recognized predisposing factors for coronary spasm.
• Alcohol (especially alcohol withdrawal)
• Emotional stress
• Exposure to cold
• Vasoconstrictor agents (e.g. beta blockers, anti-migraine drugs)
• Stimulant drugs (e.g. amphetamines and cocaine)
• Chemotherapyat the site of spasm has been documented by intravascular ultra-
sound (IVUS) (Fig. 1), in coronary spasm patients with apparently
normal coronary angiograms yet this was associated with a faster
progression rate of atheroma [14,40–42]. This is in line with the
idea that spasm is a widespread phenomenon of arterial remodel-
ling. While plaque may itself induce spasm, this is difﬁcult to prove,
but what is known is that coronary spasm can itself induce the rup-
ture of stable atherosclerotic plaque, with consequent coronary
thrombosis and myocardial infarction. Moreover, in patients with
chronic stable angina, myocardial ischaemia may also be related to
distal coronary artery spasm [43]. Furthermore, the microvascula-
ture may also demonstrate spasm, although this is more difﬁcult to
observe. For example, during myocardial infarction, there is wide-
spread microvascular hyper-reactivity, not necessarily related to
the infarct zone, and considered to be responsible in part for the
no-reﬂow phenomenon. Therefore, if a patient suspected to have
coronary spasm complaints of chest pain during a provocation test
(acetylcholine or ergonovine administration) along with direct or indi-
rect ﬁndings of myocardial ischaemia (ECG abnormalities, reduction of
coronary blood ﬂow rate, and myocardial lactate production), but
angiography is negative for spasm, microvascular spasm should be
suspected.
Thus coronary spasmmay occur in the presence or absence of coro-
nary atheroma or plaques and the two are not mutually exclusive.
Where they do occur concurrently, the prognosis is clearly worse. It is
likely that spasm and atherosclerosis share common aetiological pro-
cesses (endothelial dysfunction, arterial remodelling), but may operate
independently in causing myocardial ischaemia.
4. Diagnostic challenges
Coronary spasm may present in a variety of ways and are often
subtle. It is for this reason that delays in diagnosis are common, with
an estimated 3 months from presentation to diagnosis [29]. In some
cases, the ﬁrst (and only) manifestation may be with a sudden myocar-
dial infarction or cardiac arrest. The spectrum of symptoms, ECG chang-
es, and strong circadian pattern required for a diagnosis of coronary
spasm have been described in detail previously [1–2,4–5,13]. Notably,
despite the safety of provocation tests, these are still not commonly per-
formed [14].
Patients with chest pain, ECG ST segment elevation and normal cor-
onary arteries are usually considered to be affected by spasm if the clin-
ical scenario is consistent with the characteristics of coronary spasm
(Table 1) [13]. Myocardial infarction can develop if the spasm and is-
chaemia are sufﬁciently prolonged to induce myocyte death. Following
an acute presentation as described, patients are usually discharged on a
medication with anti-spasm properties, along with any other therapies
for co-existent atherosclerosis or LV impairment, lifestyle modiﬁcation
advice and subsequent re-evaluation in clinic. If full control of symp-
toms has been achieved, no further investigations are pursued at this
stage.
4.1. Diagnosis in speciﬁc clinical settings
(1) Patients with ECG ST segment elevation and coronary stenosis.
If concordance between clinical (ECG and echo) and angiograph-
ic ﬁndings is present for lesion localisation, stent implantation
according to the type of lesion is performed. If there are no culprit
lesions on angiography and the clinical presentation (including
risk factors) is indicative, coronary spasm treatment is initiated
and any observed, and presumed bystander, stenosis is re-
evaluated by stress testing.
(2) Patients referred to the clinic for chest pain after a stress test.
a. If positive, patients usually begin anti-ischaemic treatment or are
considered for invasive coronary investigation and management.
If spasm is present with atherosclerosis, despite the restored
Fig. 1. Evidence at angiography (A–B) and intra-vascular ultrasound (C–D) evaluation of right coronary artery spasm.
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continue to complain of chest pain due to spams episodes.
b. If negative, additional testing with invasive angiography or with
Holter ECGmonitoring can be performed. If symptoms and ischae-
mic ECG changes correlate the diagnosis is made. Unfortunately
symptomsmay not occur in a short time frame and longer record-
ings may be needed if the likelihood of spasm is high. If a patient
reports symptoms during ECGmonitoring butwithout ECG chang-
es, and the clinical scenario still ﬁts coronary spasm characteristics,
microvascular spasm may be a possibility and empirical therapy
started. They are usually re-evaluated in the clinic in order to verify
the effects of therapy on symptoms control.
(3) Patients with syncope or bradyarrhythmias.
These patientswill often requiremonitoringwithHoltermonitor-
ing to identify the cause of syncope, during which ECG changes
consistent with ischaemia may indicate a diagnosis of coronary
spasm. In this case, treatment may be initiated with revaluation
thereafter.
(4) Patient surviving a cardiac arrest with no coronary artery disease.
Once other causes of cardiac arrest have been excluded, second-
ary prevention ICD implantation is usually offered to patients in
line with guidelines. If coronary spasm is a possibility, based onprevious symptoms or other evidence, medical therapy to reduce
spasm is also coronary spasm started.
Cardiac arrest in a patient with coronary artery disease is usually
managed with standard revascularisation approaches. Coronary
spasm therapy is not considered unless symptoms or signs previ-
ously or subsequently indicate that this is a possibility. According
to international guidelines, an ICD is generally not implanted in
this setting [31].
(5) Asymptomatic coronary spasm.
Occasionally, a diagnosis of spasm may be considered if ECG
criteria are identiﬁed incidentally during Holter or prolonged
ECG monitoring despite a lack of reported symptoms. It is worth
noting that in such patients, depending on the site, duration and
the severity of the spasm, the ﬁrst symptomatic manifestation
may be a life threatening event (myocardial infarction, cardiac
arrest, syncope).4.2. Invasive diagnosis or non-invasive diagnostic tests?
A diagnosis of coronary spasm is usually made once coronary spasm
is suspected from history and investigations have been performed.
50 M. Slavich, R.S. Patel / IJC Heart & Vasculature 10 (2016) 47–53These testsmay be non-invasive or invasive ormay not be needed at all.
Indeed, as reported in Japanese Circulation Society Guidelines, coronary
angiography can be avoided altogether if a patient meets all listed
criteria for coronary spasm (Table 1) [13]. In usual clinical practice,
with the exception of Japan, myocardial spasm provocation tests are
not performed routinely because of the concern of adverse events dur-
ing drug administration. This is despite studies reporting an acceptable
safety proﬁle of acetylcholine and ergonovine intracoronary
administration,with provision of useful diagnostic andprognostic infor-
mation [14]. Moreover, in a recent Korean study, the response to ergo-
novine stimulation was assessed. Patients with positive response had
worse prognosis than patients with intermediate response [32].
5. Management
Pharmacological interventions (Table 3) have the potential to re-
duce or prevent spasmattacks, symptoms and life-treating arrhythmias.
Aside from compliance with treatment, identiﬁcation and avoidance of
precipitants are an essential component of any management plan. In
this regard it is essential to advise patients to quit smoking. Despite a
wide consensus on the role of nitrates and calcium channel antagonist,
in treating patients with coronary spasm, there remain uncertainties
about how to best manage these patients, from which agent to use
through to when to consider the use of ICD for primary prevention.
5.1. What is the best pharmacological treatment?
Calcium channel antagonists (both dihydropyridine and non-
dihydropyridine) and nitrates represent the mainstay of therapy be-
cause they reduce, prevent and resolve spasm attacks and thus angina
and arrhythmias. These beneﬁcial effects are mediated suppressing
Ca2+ inﬂow into the vascular smooth muscle and through the nitrate
metabolisation to NO, both resulting in relaxation of vascular smooth
muscle and vasodilation. Prospective double-blind studies with calcium
channel antagonists compared with nitrates have reported efﬁcacy for
both agents to a similar degree, in reducing spasm occurrence [44].
Some have argued for use of both agents concurrently [13,45–58]. Im-
portantly, the drugs can be used safely, without adverse reactions, and
the dosage should be increased up to the maximal tolerated dose.
Monotherapy with either drug alone is based on patient choice and
circumstance.
In some cases a combination of 2 calcium antagonists
(dihydropyridine and non-dihydropyridine) may be required for
more severe symptoms, although few data exist for this approach.
Non-selective β-blockers (like propranolol) convert the effects of
sympathetic stimulation into a pure a-adrenergic vasoconstrictor
response, thus they can exacerbate and prolong vasospasm in these
patients [62]. However, since coronary spasm can occur in patients
with stable angina as well, concomitant use of calcium channel antago-
nists and selective β-blockers can be considered in coronary spasm
patients with signiﬁcant coronary artery stenosis, preventing effort
related pain, but it should be noted that this can exacerbate spasm
recurrence.Table 3
Current therapeutic approaches for patients with coronary spasm.
• Long-acting calcium antagonists (both dihydropyridine and non-dihydropyridine)
• Long-acting nitrates
• Nicorandil
• Magnesium
• Antioxidants (vitamins C and E)
• Fluvastatin
• a-blockage
• Selective thromboxane A2 synthetase inhibition
• Rho-kinase inhibitor fasudil
• Iloprost
• Selective serotonin receptor blockageNotably, especially when symptoms are under control, medications
should not be discontinued. As reported by Takagi et al., discontinuing
or reducing medication is associated with symptom recurrence, higher
incidence of lethal arrhythmic events and non-fatal myocardial infarc-
tion [59–61]. Drugs should preferably be taken nocturnally because of
the reported circadian pattern and risk of events in the early morning.
5.2. The natural history of variant angina
Despite the therapeutic approaches advocated by clinical evidence
and endorsed by guidelines, prevention of coronary spasm remains
difﬁcult.
In an old survey conducted on 286 patients, the rates of therapeutic
success, deﬁned as the resolution of angina attacks, were high (above
85%), and were dependent on the therapy itself [63]. However, the suc-
cess of coronary spasm treatment should not be constrained to the
reduction of symptoms alone but should also aim to prevent the under-
lying episodes of spasm. Symptomsand spasmmaynot always correlate
and only approximately the 30% of ECG changes consistent with spasm
are associated with symptoms, especially when they last for less than
5 min [64]. On the hand, in 35 patients' sample, impaired myocardial
fatty acid metabolism was still present after one year of spasm therapy,
thought to be related to ongoing persistent silent ischaemic events [65].
Thus, absence of symptoms is not a wholly reliable parameter with
which to judge therapeutic efﬁcacy. Persistence of coronary spasm de-
spite optimal therapy exposes patients to potentially life-threatening
events (arrhythmias and myocardial infarction) [66].
5.3. What other options exist?
Several studies have evaluated alternative therapies for coronary
spasm including nicorandil, statins, aspirin, magnesium, Vitamins C
and E, Iloprost, alpha receptor blockade, selective serotonin receptor in-
hibitors, and selective thromboxane A2 synthetase inhibition. Although
considered effective in certain patients, in speciﬁc clinical settings, there
is a lack of evidence and consensus on their use and further studies are
needed to ascertain their effectiveness in daily clinical practice. All of
these drugs can be considered if a patient is still symptomatic despite
optimal therapy.
5.3.1. Nicorandil
Nicorandil opensATP-sensitive potassium channels and has a nitrate
like effect [67]. As such itwould be expected to have beneﬁcial effects on
spasm, and indeed Kishida et al. has demonstrated its efﬁcacy when
compared with placebo in reducing symptoms and ECG changes in
coronary spasm [68]. Lablanche et al., in a comparative study between
nifedipine and nicorandil, reported similar efﬁcacy and no signiﬁcant
differences between the two groups for prevention of coronary
spasm [69].
5.3.2. Statins
Statins have also been tested in this context. Fluvostatin was evalu-
ated in a randomised open-label trial of 64 patients with coronary
spasm andwas associated with a signiﬁcant reduction in coronary reac-
tivity to intracoronary injection of acetylcholine. This effect was postu-
lated to be driven by the pleiotropic effect of statins, speciﬁcally due
to improvement of endothelial dysfunction and a reduction of calcium
sensitivity [70].
5.3.3. Aspirin
Small doses of aspirin have vasodilating properties and platelet-
inhibiting effects, mediated by blocking thromboxane A2, which has
powerful vasoconstrictor properties; on the other hand large doses in-
hibit prostacyclin production aggravating coronary vasospasm and
may worsen symptoms and spasm although this is not proven [73].
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Long-term supplementation with magnesium had also been shown
to prevent coronary spasm and it is particularly beneﬁcial in coronary
spasm recurrence during effort and after alcohol consumption [74–77].
Increased activity of the Rho-kinase system causes hypercontraction
of vascular smoothmuscle. Fasudil, a selective Rho-kinase inhibitor, has
been demonstrated to attenuate coronary vasospasm and may have
therapeutic potential [78].
5.3.5. Others
Angiotensin receptor blockers are known to abolish the develop-
ment of nitrate tolerance [71]. Whether this therapy can reduce the
frequency of the attacks with or without nitrate use requires further
study. Since autonomic dysfunction is also implicated in the develop-
ment of spasm, balanced therapy with alpha receptor agonists and
antagonists could also be tried [72].
6. Refractory variant angina
When vasospastic attacks cannot be prevented, relieved or sup-
pressed by a combination of at least two coronary vasodilators therapy
(calcium channel antagonists and nitrates) the patient is considered to
have refractory variant angina. According to a Japanese prevalence
study, these patients represent 13% of the coronary spasm population
and, since spasm attacks are not fully prevented, they should be consid-
ered at high risk for myocardial infarction, malignant arrhythmias,
syncope, and sudden death [13]. Patients are usually smokers, normo-
tensive and are younger than those with usual coronary spasm.
In refractory variant angina two classes of patients should be consid-
ered: the true non-responder, and those who are refractory secondary
to poor compliancewith therapy or life style advice (i.e. smoking cessa-
tion, alcohol consumption). True non-responders can be further split
into those who are symptomatic and those who are asymptomatic.
In both groups efforts still need to be made to decide the most ap-
propriate therapeutic approach and clinical management, and asymp-
tomatic patients are even more difﬁcult to monitor throughout the
time and evaluate the therapy efﬁcacy. Once standard management
has been attempted other less commonly used drugs can also be tried,
such as those listed earlier [66]. Failing these, other non-drug options in-
clude the following:
Brachytherapy: at the sites of spasm has been developed as an option
for refractory coronary spasm, although it has to beweighed carefully
because it exposes the patient to a signiﬁcant risk of thrombosis in the
site of radiation. Immediately after the procedure, a reﬂex vasocon-
striction rise has been documented, which progressively reduces,
until there is a complete loss of vasomotion and spasm. Some
evidence suggests that it is beneﬁcial, with a study of 18 patients
experiencing fewer spasm attacks, who took Clopidogrel for one
year followed by aspirin for life to prevent thrombosis [79–81].
Coronary stenting: In patients with refractory coronary spasm, coro-
nary stenting can be considered as an additional treatment in
carefully selected and clinically unstable patients. The long terms re-
sults are unpredictable, and further studies are still needed. It has
been performed in patients without signiﬁcant stenosis at the
spasm site and in patients with concomitant atherosclerotic lesions
as well. In the latter, stent implantation can improve angina of effort
but spasm often occurs in different segments of the treated artery,
probably due to the diffuse nature of the disease. For this reason,
concomitant drug therapy should bemaintained. Stent implantation
is associatedwith risk of in-stent thrombosis and restenosis [82–84],
although interestingly, despite their beneﬁt compared with bare
metal stents, drug-eluting stents adopted in coronary spasm, have
a negative effect because they induce endothelial dysfunction,which leads to a paradoxical coronary vasoconstriction of the
adjacent vessel segments [85–86].
Surgery: Coronary artery bypass surgery for coronary spasm patients
without obstructive coronary artery disease has been associated
with high morbidity, mortality and recurrence of angina and is not
an advocated treatment option. However, in rare cases with medi-
cally intractable or even life-threatening variant angina surgical in-
tervention can be considered. Historical case reports of bypass
grafting of the spasmodic artery associated with a plexectomy sug-
gest that this may be efﬁcacious for patients with focal spasm. Sym-
pathetic denervation has also been justiﬁed by the adrenergic role in
the development of the vasoconstriction [87–89].
7. Risk stratiﬁcation and ICD therapy
Severe myocardial ischaemia caused by coronary spasm can lead to
life threatening ventricular arrhythmias. In addition patients with coro-
nary spasmhave increased ventricular irritability and prolonged QT dis-
persion, compared with controls, particularly during symptom-free
periods [90–92]. For these reasons, coronary spam patients are consid-
ered at high risk for malignant arrhythmias and ICD implantation has
been advocated in this group.
Coronary spasm patients resuscitated from a cardiac arrest have a
poorer prognosis, from further arrhythmias and death when compared
with coronary spasm patients with other presentations [59]. In addition
a recent study by Matsue et al. retrospectively evaluated records of pa-
tients with coronary spasm receiving a device for secondary prevention,
and demonstrated a high ICD therapy rate for ventricular arrhythmias
[93]. However, even in the absence of this data, current guidelines
permit and recommend ICD implantation for anyonewith failed sudden
death and normal coronary arteries on angiography.
In contrast, ICD implantation for primary prevention of sudden
cardiac death (SCD) remains an area of uncertainty. This is primarily
so as risk stratiﬁcation is poorly established or understood for coronary
spasm, although several features have been proposed to identify those
at greatest risk of sudden death:
Symptoms:Mesiel et al. demonstrated that coronary spasm patients
manifesting a run of a dangerous arrhythmia, prior to their event,
had persistence of symptoms despite medical treatment. They
postulated that ongoing symptoms on medical therapy should be
regarded as a marker of inadequate treatment, and thus such indi-
viduals should be considered for ICD [94]. Unfortunately symptoms
such as chest pain are not reliable parameters to guide risk, especial-
ly as episodes may be short, require several minutes before mani-
festing and 70–80% of individuals are asymptomatic.
Risk behaviour: Several studies have demonstrated higher recur-
rences of symptoms and sudden death in patients with coronary
spasm who smoke, use illicit substances and/or discontinued medi-
cations [13,34,37,59,61,92,94].
Provocation response: Patientswith a positive provocation test (ergo-
novine, acetylcholine) seem to have a worse prognosis when com-
pared with patients with an intermediate response [32]. Moreover,
a provocation test identifying multi-vessel spasm is associated
with more extensive myocardial ischaemia and has been associated
with an adverse prognosis [14].
In summary, there are currently no accepted criteria for
recommending an ICD for primary prevention of SCD in patients
with coronary spasm. Those with multi-vessel ischaemia on provo-
cation testingmay derive beneﬁt but this requires further trial evidence
before it can be advocated in guidelines. Decisions are currently made
on an individual patient basis, determined by local practice and
consensus.
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Coronary spasm should be considered as resulting from extensive
vasomotor and endothelial dysfunction of the coronary circulation. It re-
mains highly challenging to diagnose, but has important symptomatic
and prognostic implications.While medications are available andmost-
ly effective for symptom control, suppression of spasm remains a prob-
lem. Multiple alternative therapies have been proposed and tested, but
currently there is little consensus on their use. The most important
prognostic therapy, ICD implantation is expensive and better risk strat-
iﬁcation tools are urgently needed to guide their use for primary pre-
vention of SCD.
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